Literature DB >> 16309192

Evaluation of tumor malignancy in esophageal squamous cell carcinoma using different characteristic factors.

Tatsuya Miyazaki1, Hiroyuki Kato, Hitoshi Kimura, Takanori Inose, Ahmad Faried, Makoto Sohda, Masanobu Nakajima, Yasuyuki Fukai, Norihiro Masuda, Ryokuhei Manda, Minoru Fukuchi, Katsuhiko Tsukada, Hiroyuki Kuwano.   

Abstract

BACKGROUND: We have been investigating various molecules correlated with the malignancy of esophageal squamous cell carcinoma and, in the present study, we examined the correlation of four of them (KAI1, FAK, EphA2, Ki-67 labeling index) with the prognosis of affected patients. Furthermore, the use of biopsy samples was studied to evaluate whether the grade of tumor malignancy can be determined before treatment in a clinical setting.
MATERIALS AND METHODS: Tissue specimens that had been surgically removed from 91 patients with thoracic esophageal cancer and 247 biopsy samples were examined. The malignancy index (MI) was defined in terms of the KAI1, FAK and EphA2 scores and the Ki-67 labeling index, and the reliability and utility of the correlation between MI and prognosis was evaluated.
RESULTS: The mean 5-year survival rate of patients with MI=0 was 100%, while that of patients with MI=1, 2 and 3 was 70%, 48% and 10%, respectively. Patients with MI=4 all died, with the exception of one who has been observed for 3 years. The rate of concordance between the biopsy samples and surgical specimens was 79.4% for KAI1, 88.2% for FAK and 73.5% for EphA2, and the rates of concordance for 1, 2, 3, 4, 5, 6, 7 and 8 biopsy samples were 66.7%, 64.1%, 74.5%, 90.7%, 91.7%, 83.3%, 100% and 100%, respectively.
CONCLUSION: It may be feasible to evaluate the malignancy of tumor cells and to predict patient outcome by using multiple marker molecules. It is anticipated that such data will accelerate the development of "tailor-made" therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309192

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Current approaches to fine mapping of antigen-antibody interactions.

Authors:  W Mark Abbott; Melissa M Damschroder; David C Lowe
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

2.  Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma.

Authors:  Nazia Syed; Mustafa A Barbhuiya; Sneha M Pinto; Raja Sekhar Nirujogi; Santosh Renuse; Keshava K Datta; Aafaque Ahmad Khan; Kotteazeth Srikumar; T S Keshava Prasad; M Vijaya Kumar; Rekha Vijay Kumar; Aditi Chatterjee; Akhilesh Pandey; Harsha Gowda
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

3.  Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.

Authors:  Xiying Shang; Xinjian Lin; Stephen B Howell
Journal:  Cell Commun Signal       Date:  2014-10-25       Impact factor: 5.712

4.  Prognostic role of CD82/KAI1 in multiple human malignant neoplasms: a meta-analysis of 31 studies.

Authors:  Jundong Zhu; Chenkui Miao; Shouyong Liu; Ye Tian; Chao Zhang; Chao Liang; Aiming Xu; Qiang Cao; Zengjun Wang
Journal:  Onco Targets Ther       Date:  2017-12-06       Impact factor: 4.147

5.  Overexpression of KAI1/CD82 suppresses in vitro cell growth, migration, invasion and xenograft growth in oral cancer.

Authors:  Juan Chai; Liangzhi Du; Jun Ju; Chao Ma; Zhiyuan Shen; Xiangming Yang; Liang Liang; Qianwei Ni; Moyi Sun
Journal:  Mol Med Rep       Date:  2017-02-09       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.